Free Trial

Rani Therapeutics (RANI) Stock Price, News & Analysis

Rani Therapeutics logo
$0.53 -0.01 (-1.63%)
As of 10:03 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Rani Therapeutics Stock (NASDAQ:RANI)

Key Stats

Today's Range
$0.53
$0.58
50-Day Range
$0.41
$0.70
52-Week Range
$0.39
$3.75
Volume
125,730 shs
Average Volume
1.16 million shs
Market Capitalization
$38.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.33
Consensus Rating
Buy

Company Overview

Rani Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

RANI MarketRank™: 

Rani Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 353rd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rani Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Rani Therapeutics has received no research coverage in the past 90 days.

  • Read more about Rani Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Rani Therapeutics are expected to grow in the coming year, from ($1.01) to ($0.84) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rani Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rani Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Rani Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.12% of the float of Rani Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rani Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Rani Therapeutics has recently decreased by 86.26%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Rani Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Rani Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.12% of the float of Rani Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rani Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Rani Therapeutics has recently decreased by 86.26%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Rani Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Rani Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 4 people have searched for RANI on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Rani Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    45.08% of the stock of Rani Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 30.19% of the stock of Rani Therapeutics is held by institutions.

  • Read more about Rani Therapeutics' insider trading history.
Receive RANI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RANI Stock News Headlines

Wall Street Zen Upgrades Rani Therapeutics (NASDAQ:RANI) to Hold
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
RANI: Second Quarter Financial Results
Rani (RANI) Q2 Net Loss Improves 16%
Rani Therapeutics Holdings, Inc. (RANI) - Yahoo Finance
See More Headlines

RANI Stock Analysis - Frequently Asked Questions

Rani Therapeutics' stock was trading at $1.37 at the beginning of the year. Since then, RANI stock has decreased by 60.6% and is now trading at $0.5398.

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) released its quarterly earnings results on Thursday, August, 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01.

Rani Therapeutics (RANI) raised $100 million in an IPO on Friday, July 30th 2021. The company issued 6,666,667 shares at $14.00-$16.00 per share.

Rani Therapeutics' top institutional shareholders include Armistice Capital LLC (4.99%), Janney Montgomery Scott LLC (0.09%) and Well Done LLC (0.09%). Insiders that own company stock include South Cone Investments Limited, Talat Imran, Kate Mckinley and Cortes Isidoro Alfonso Quiroga.
View institutional ownership trends
.

Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rani Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Honeywell International (HON), CrowdStrike (CRWD), Cisco Systems (CSCO), Intel (INTC) and CocaCola (KO).

Company Calendar

Last Earnings
8/07/2025
Today
8/29/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RANI
CIK
1856725
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

High Price Target
$9.00
Low Price Target
$4.00
Potential Upside/Downside
+1,258.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.91)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$30.02 million
Net Margins
N/A
Pretax Margin
-4,367.17%
Return on Equity
-1,258.76%
Return on Assets
-97.97%

Debt

Debt-to-Equity Ratio
2.75
Current Ratio
0.54
Quick Ratio
0.54

Sales & Book Value

Annual Sales
$1.03 million
Price / Sales
37.67
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.13) per share
Price / Book
-4.15

Miscellaneous

Outstanding Shares
71,870,000
Free Float
39,470,000
Market Cap
$38.80 million
Optionable
Optionable
Beta
-0.02
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:RANI) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners